Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
Comunicato Precedente
Comunicato Successivo
The two abstracts selected in the top 10 at the conference both highlight important subgroup results from the randomised-controlled-period (RCP) of the VALIANT Phase 3 study covering the treatment effect of pegcetacoplan at 26 weeks in patients with nephrotic range proteinuria at baseline, and the effect of pegcetacoplan in adolescents at 26 weeks.
Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi says, "The large number of oral presentations, including one achieving the highest ranking of all ERA abstracts and a second in the top 10, reflects the importance of the data and research outputs being generated from our work aimed at advancing treatments for rare kidney conditions."
Key data to be presented at ERA 2025
glomerulonephritis (IC-MPGN) in the US and Europe.
Presenter: Carly Rich
Room: XWall 1 Mozart Symphony No. 40
Date: 5 June 2025
Time: 13:12 CEST
VALIANT Phase 3 study in patients with C3G or
Primary (Idiopathic) IC-MPGN
Presenter: Antonio Mastrangelo
Room: Hall F1
Date: 6 June 2025
Time: 08:15 CEST
MPGN in the VALIANT Phase 3 trial
Presenter: Antonio Mastrangelo
Room: Hall F1
Date: 6 June 2025
Time: 08:30 CEST
immunosuppression in VALIANT
Presenter: David Kavanagh
Room: Hall F1
Date: 6 June 2025
Time: 09:30 CEST
MPGN: a Delphi consensus of European experts
Presenter: Fernando Caravaca-Fontán
Room: Strauss Wiener Blut
Date: 6 June 2025
Time: 13:06 CEST
trial show sustained efficacy
Presenter: Fadi Fakhouri
Room: The Square
Date: 6 June 2025
Time: 15:00 CEST
Presenter: Michiel Oosterveld
Room: Focused Oral Room 3
Date: 6 June 2025
Time: 15:54 CEST
Presenter: Daniel Gale
Room: Focused Oral Room 3
Date: 6 June 2025
Time: 16:06 CEST
About the VALIANT Study
The VALIANT Phase 3 study (NCT05067127) was a randomised, placebo-controlled, double-blinded, multi-centre study evaluating pegcetacoplan efficacy and safety in 124 patients who were 12 years of age and older, with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include adolescent and adult patients, with native and post-transplant kidneys. During the 26-week randomised-controlled-period (RCP) of VALIANT, patients received twice weekly subcutaneous pegcetacoplan or placebo. The RCP was followed by a 26-week open-label period (OLP) in which all patients received pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (UPCR) at week 26 compared to baseline.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn, BlueSkyX
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-showcases-breadth-of-data-in-c3g-primary-ic-mpgn-at-era-2025,c4158688
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/sobi-showcases-breadth-of-data-in-c3gprimary-ic-mpgn-at-era-2025-302472985.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
